Mattia Galli/LinkedIn
Nov 12, 2025, 05:16
Mattia Galli on The Choice in ASCVD: Aspirin or P2Y12 Inhibitor Monotherapy?
Mattia Galli, Assistant Professor at Sapienza University of Rome, Associate Editor of European Heart Journal, shared on LinkedIn:
”Should P2Y12 inhibitor be preferred over aspirin for long treatment in ASCVD patients?
All you need to know in this balanced, yet comprehensive State-of-the-Art review published in the European Heart Journal.”
Read the full article in EHJ.
Article: Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?
Authors: Mattia Galli, Jurrien ten Berg, Marco Valgimigli, Davide Capodanno, Felice Gragnano, Takeshi Kimura, Deepak L Bhatt, C Michael Gibson, Roxana Mehran, Dominick J Angiolillo
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology